In contrast, an Italian registry study showed that only 5% had a PDC with PCSK9 mAb treatment below 0.8.15 Patients were recruited in centres highly experienced in dyslipidaemia management, which may have resulted in closer follow-up, compared with a nationwide cohort. This evidence concerns the gene PCSK9 and inherited lipid metabolism disorder.